Intravenous immunoglobulin (IVIg) is used to treat a wide range of disorders, and preparations are extracted from pools of greater than 10,000 donors. Many studies have demonstrated antibodies to hepatitis B and C, HIV, and even syphilis in IVIg preparations, which can cause confusion and potential misinterpretation of serologic testing. We present a case of a 38-year-old man with diffuse large B-cell lymphoma who received 2 U of packed RBCs at initial diagnosis; 6 months later, screening infectious disease testing for HPC harvesting was positive for anti–hepatitis B core antibody (anti-HBc), anti– hepatitis B surface antibody (anti-HBs), and HTLV 1/2 IgG antibodies. The patient denied any high-risk behavior or previous HBV vaccination, which raised concern from the clinical team for transfusion-transmitted disease, and the transfusion service was asked to investigate. Investigational testing revealed that HBs antigen, anti-HBc IgM, HBV DNA by PCR, and HTLV 1/2 DNA by PCR were all negative, and hepatic function panels were normal. A survey of the patient’s medical chart revealed that the patient had received IVIg treatment every 3 weeks for the last 6 months for hypogammaglobulinemia. Given that investigational laboratory results showed no evidence of active or chronic hepatitis infection, we concluded that these positive serologic results were due to passive IgG antibodies in IVIg. The IVIg treatments were stopped, and 3 weeks later, serologic testing for HBV and HTLV IgG antibodies were negative, confirming that the original serology was falsely positive. Passive transfer of antibodies to a variety of diseases from IVIg products is well documented but not often considered when interpreting serologic results in the laboratory and in clinical medicine. Better communication between laboratory professionals and clinicians about the effects of IVIg on serologic testing will lead to less misinterpretation of results and better multidisciplinary patient care.